Chen, Lu http://orcid.org/0000-0001-9347-291X
Krekels, Elke H. J. http://orcid.org/0000-0001-6006-1567
Heijnen, Anne R.
Knibbe, Catherijne A. J. http://orcid.org/0000-0001-9893-4415
Brüggemann, Roger J. http://orcid.org/0000-0002-7618-725X
Article History
Accepted: 22 November 2022
First Online: 6 January 2023
Declarations
:
: The work of Lu Chen was supported by the China Scholarship Council.
: No disclosures are applicable for this work. Disclosures outside of this work: RJB has served as a consultant to Astellas Pharma, Inc., F2G, Amplyx, Gilead Sciences, Merck Sharp & Dohme Corp., Mundipharma, and Pfizer, Inc., and has received unrestricted and research grants from Astellas Pharma, Inc., Gilead Sciences, Merck Sharp & Dohme Corp., and Pfizer, Inc. All contracts were through Radboud University Medical Center, and all payments were invoiced by Radboud University Medical Center. None of the other authors has a conflict of interest to declare.
: Each clinical study involved in this paper received ethics approval.
: Not applicable.
: Not applicable.
: Part of the data that support the findings of this study is available from Radboud University Medical Center but restrictions apply to the availability of these data. Data from Merck & Co were obtained under confidentiality and were used under license for the current study, thus are not publicly available.
: The NONMEM code for the final model can be found in the ESM.
: Conception and design of the research: LC, EHJK, CAJK, and RJB; data collection: RJB; data analysis: LC and ARH; interpretation of findings: LC, EHJK, ARH, CAJK, and RJB; drafting the manuscript: LC; critical revision of manuscript: EHJK, ARH, CAJK, and RJB; and approval of the final manuscript: LC, EHJK, ARH, CAJK, and RJB.